Skip to main content

Table 1 Clinicopathological characteristics of 215 breast cancer patients and univariate analysis of established prognostic factors for disease-free and overall survival

From: Tumour Fas ligand:Fas ratio greater than 1 is an independent marker of relative resistance to tamoxifen therapy in hormone receptor positive breast cancer

  

Disease-free survival

Overall survival

Factor

Number of patients (%)

P

RR (95% CI)

P

RR (95% CI)

Menopausal status (n = 209)

     

   Premenopausal

62 (29.7)

0.121

1.73 (0.86–3.47)

0.061

2.49 (0.96–6.45)

   Postmenopausal

147 (70.3)

    

Histological grading (n = 206)

     

   I

101 (49.0)

0.113

1.36 (0.93–2.0)

0.003

1.93 (1.25–3.0)

   II

81 (39.3)

    

   III

24 (11.7)

    

Lymph node status (n = 203)

     

   Negative

116 (57.1)

0.009

2.22 (1.22–4.03)

0.095

1.85 (0.9–3.82)

   Positive

88 (42.9)

    

Tumour size (n = 205)

     

   pT1

93 (45.4)

0.001

1.85 (1.29–2.65)

<0.001

2.3 (1.53–3.45)

   pT2

96 (46.8)

    

   pT3 and pT4

16 (7.8)

    

Oestrogen receptor status (n = 208)

     

   ≤ 10 fmol/mg

74 (35.6)

0.73

1.12 (0.58–2.16)

0.547

1.29 (0.56–2.99)

   >10 fmol/mg

134 (64.4)

    

Progesterone receptor status (n

= 205)

    

   ≤ 10 fmol/mg

118 (57.6)

0.056

0.57 (0.33–1.01)

0.636

0.84 (0.42–1.67)

   >10 fmol/mg

87 (42.4)

    

Fas ligand : Fas ratio (n = 211)

     

   ≤ 1

139

0.023

1.92 (1.09–3.35)

0.172

1.61 (0.81–3.2)

   >1

72

    
  1. CI, confidence interval; RR, relative risk.